Not my paper, theirs -- and specifically in higher-risk persons where the drug was claimed to reduce hospitalizations and deaths:https://www.nejm.org/doi/full/10.1056/NEJMoa2502457In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection. (Funded by the National Institute for Health and Care Research, and others; PANORAMIC ISRCTN number, 2021-005748-31;.......(Click link to read more)